Stock Analysis on Net
Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

$24.99

Balance Sheet: Assets

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Paying user area

Try for free

Bristol-Myers Squibb Co. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Bristol-Myers Squibb Co., consolidated balance sheet: assets

US$ in millions

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Cash and cash equivalents
Marketable debt securities
Net trade receivables
Alliance, royalties, VAT and other
Receivables
Inventories
Income taxes
Research and development
Contract assets
Equity investments
Restricted cash
Other
Other current assets
Current assets
Property, plant and equipment
Goodwill
Other intangible assets
Deferred income taxes
Marketable debt securities
Equity investments
Operating lease right-of-use assets
Inventories
Pension and postretirement
Research and development
Restricted cash
Receivables and convertible notes
Other
Other non-current assets
Non-current assets
Total assets

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Assets: Selected Items

Balance sheet item Description The company
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Bristol-Myers Squibb Co. current assets decreased from 2021 to 2022 but then increased from 2022 to 2023 not reaching 2021 level.
Property, plant and equipment Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Bristol-Myers Squibb Co. property, plant and equipment increased from 2021 to 2022 and from 2022 to 2023.
Non-current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Bristol-Myers Squibb Co. non-current assets decreased from 2021 to 2022 and from 2022 to 2023.
Total assets Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Bristol-Myers Squibb Co. total assets decreased from 2021 to 2022 and from 2022 to 2023.

Current Assets: Selected Items

Balance sheet item Description The company
Cash and cash equivalents Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Bristol-Myers Squibb Co. cash and cash equivalents decreased from 2021 to 2022 but then slightly increased from 2022 to 2023.
Marketable debt securities Amount of investment in marketable security, classified as current. Bristol-Myers Squibb Co. marketable debt securities decreased from 2021 to 2022 but then slightly increased from 2022 to 2023.
Net trade receivables Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Bristol-Myers Squibb Co. net trade receivables increased from 2021 to 2022 and from 2022 to 2023.
Inventories Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. Bristol-Myers Squibb Co. inventories increased from 2021 to 2022 and from 2022 to 2023.